Psoriatic Arthritis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Psoriatic Arthritis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 5 companies, in the next 180 days.
September 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Korean Post-marketing Surveillance for Xeljanz XRNCT04876781observationalNumber of Participants With Treatment Emergent Adverse Events (AEs) | — | Recruiting | 2026-09-22 | in 33 d | 2026-08-03 |
| ABBV | AbbVie | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabNCT06100744Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30) | Phase 3 | Recruiting | Sep 2026 | ≤ 41 d | 2026-07-31 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | A Study of SPY072 in Rheumatic DiseaseNCT07148414Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP) | Phase 2 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-06-05 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ZBH | Zimmer Biomet | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating SystemNCT03626038Re-operation | Not applicable | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-02-13 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics AG | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) | Phase 3 | Recruiting | 2027-01-15 | in 148 d | 2026-08-12 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics AG | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) | Phase 3 | Active, not recruiting | 2027-02-04 | in 168 d | 2026-08-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Psoriatic Arthritis
most recently updated first102 studies match. Showing the first 100 of 102 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisNCT06869551Time to first flare during the withdrawal period | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo | Juvenile Psoriatic Arthritis | 60 | 2025-03-13 | 2030-03-06 | in 1,294 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisNCT04527380results2025-06-05Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period) | Phase 3 | Active, not recruiting | Drug: Ixekizumab, Adalimumab | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | 101 | 2021-04-13 | 2024-02-19actual | — | 2026-08-12 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) | Phase 3 | Active, not recruiting | Drug: Sonelokimab, Placebo | Arthritis, Psoriatic | 960 | 2024-10-15 | 2027-02-04 | in 168 d | 2026-08-12 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) | Phase 3 | Recruiting | Drug: Sonelokimab, Placebo, Risankizumab | Arthritis, Psoriatic | 600 | 2024-10-15 | 2027-01-15 | in 148 d | 2026-08-12 |
| PFE | Pfizer | $155.3B | Korean Post-marketing Surveillance for Xeljanz XRNCT04876781observationalNumber of Participants With Treatment Emergent Adverse Events (AEs) | — | Recruiting | Drug: Tofacitinib XR | Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis | 200 | 2022-01-12 | 2026-09-22 | in 33 d | 2026-08-03 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabNCT06100744Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30) | Phase 3 | Recruiting | Drug: Adalimumab, Risankizumab | Juvenile Psoriatic Arthritis | 40 | 2024-07-08 | Sep 2026 | ≤ 41 d | 2026-07-31 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic ArthritisNCT05616871observationalPercentage of Participants Achieving Disease Activity in Psoriatic Arthritis (DAPSA): score <=14 | — | Completed | — | Psoriatic Arthritis | 464 | 2022-12-15 | 2026-06-11actual | — | 2026-07-27 |
| ABBV | AbbVie | $457.5B | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)NCT03671148results2022-03-02Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 | Phase 3 | Completed | Biological: Placebo, Risankizumab | Psoriatic Arthritis (PsA) | 444 | 2019-03-07 | 2020-06-22actual | — | 2026-07-20 |
| SNY | Sanofi | — | A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi ArabiaNCT06714461observationalNumber of healthcare professionals who recall receiving and reading the additional risk minimization measures material for leflunomide distributed in 2022 | — | Completed | Drug: Leflunomide | Rheumatoid Arthritis, Psoriatic Arthritis | 302 | 2025-05-05 | 2026-05-14actual | — | 2026-06-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy | Phase 4 | Recruiting | Drug: Tirzepatide | Psoriatic Arthritis, Overweight or Obesity | 200 | 2025-03-06 | Nov 2027 | ≤ 467 d | 2026-06-11 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisNCT07223138Long-term safety and tolerability of sonelokimab: | Phase 3 | Enrolling by invitation | Drug: Sonelokimab | Arthritis, Psoriatic | 1,560 | 2025-11-13 | 2028-02-04 | in 533 d | 2026-06-11 |
| SYRE | Spyre Therapeutics, Inc. | $9.5B | A Study of SPY072 in Rheumatic DiseaseNCT07148414Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP) | Phase 2 | Active, not recruiting | Drug: SPY002-072, Placebo | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease | 285 | 2025-08-21 | 2026-10-31 | in 72 d | 2026-06-05 |
| LLY | Eli Lilly and Company | $1.15T | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightNCT06588296Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction | Phase 3 | Completed | Drug: Ixekizumab, Tirzepatide | Psoriatic Arthritis, Obesity | 279 | 2024-09-24 | 2025-11-18actual | — | 2026-05-13 |
| ABBV | AbbVie | $457.5B | Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic ArthritisNCT04433442observationalNumber of Participants who Reported Adverse Events | — | Completed | — | Psoriasis, Psoriatic Arthritis | 2,324 | 2020-08-04 | 2025-06-13actual | — | 2026-04-27 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsNCT04908202results2025-10-24Percentage of Participants With ACR 20 Response at Week 16 | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Psoriatic Arthritis | 670 | 2021-07-13 | 2024-09-05actual | — | 2026-04-23 |
| 068270.KS | Celltrion | $30.7B | A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and PsNCT05866614observationalevaluation of adverse events of special interest (AESI) | — | Active, not recruiting | Drug: Remsima IV, Remsima SC | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis | 881 | 2023-01-13 | Mar 2027 | ≤ 223 d | 2026-03-31 |
| ABBV | AbbVie | $457.5B | An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic ArthritisNCT06764693observationalNumber of participants that show persistence in treatment until 24 months | — | Recruiting | — | Psoriatic Arthritis | 1,200 | 2025-01-31 | Jan 2029 | ≤ 895 d | 2026-02-17 |
| ZBH | Zimmer Biomet | $18.9B | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating SystemNCT03626038Re-operation | Not applicable | Active, not recruiting | Device: A.L.P.S. Proximal Humerus Plating System | Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture | 135 | 2018-06-19 | Dec 2026 | ≤ 133 d | 2026-02-13 |
| ABBV | AbbVie | $457.5B | A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic ArthritisNCT04541810observationalPercentage of Participants With Adverse Events | — | Completed | — | Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | 2,369 | 2021-01-26 | 2025-12-31actual | — | 2026-02-12 |
| ABBV | AbbVie | $457.5B | Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisNCT06865105Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response | Phase 2 | Recruiting | Drug: Lutikizumab, Risankizumab | Psoriatic Arthritis | 120 | 2025-04-11 | Dec 2027 | ≤ 498 d | 2025-12-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterNCT05413044observationalIncidence Rate of Overall Malignancies | — | Completed | — | Rheumatoid Arthritis, Psoriatic Arthritis | 140,706 | 2019-07-01 | 2025-08-22actual | — | 2025-12-08 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish DatabaseNCT05421442observationalIncidence Rates of Overall Malignancies | — | Completed | — | Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | 38,396 | 2019-06-13 | 2025-08-22actual | — | 2025-12-08 |
| AMGN | Amgen | $229.9B | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisNCT05767047Number of Participants with Adverse Events | Phase 3 | Recruiting | Drug: Apremilast | Behçet's Disease, Juvenile Psoriatic Arthritis | 48 | 2023-03-23 | 2036-03-17 | in 3,497 d | 2025-12-01 |
| PFE | Pfizer | $155.3B | Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical PracticeNCT04517669results2025-10-14observationalPercentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 | — | Completed | — | Psoriatic Arthritis | 116 | 2021-05-17 | 2024-07-30actual | — | 2025-10-14 |
| ABBV | AbbVie | $457.5B | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)NCT03104400results2022-01-25Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Phase 3 | Completed | Drug: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab | Psoriatic Arthritis | 1,705 | 2017-04-27 | 2019-09-26actual | — | 2025-09-22 |
| ABBV | AbbVie | $457.5B | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugNCT03104374results2022-01-25Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Phase 3 | Completed | Drug: Placebo, Upadacitinib | Psoriatic Arthritis | 642 | 2017-05-01 | 2019-07-23actual | — | 2025-09-11 |
| AMGN | Amgen | $229.9B | Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice ConditionsNCT03106051observationalPercentage of patients with an improvement of ≥ 1 points on the Physician's Global Assessment (PGA) scale on visit 3 compared to baseline on the Physician's Global Assessment scale (PGA; scale from 0-4) | — | Completed | — | Arthritis, Psoriatic | 526 | 2016-02-18 | 2018-07-31actual | — | 2025-09-03 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in IndiaNCT05855967results2025-08-22Number of Participants Reporting Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) and AEs of Special Interests (AESIs) From Week 0 to Week 24 | Phase 4 | Completed | Drug: Ixekizumab | Plaque Psoriasis, Psoriatic Arthritis | 250 | 2023-06-27 | 2024-08-08actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyNCT03675308results2022-02-24Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 | Phase 3 | Active, not recruiting | Biological: Placebo, Risankizumab | Psoriatic Arthritis | 964 | 2019-03-25 | 2020-10-08actual | — | 2025-08-05 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentNCT04908189results2025-04-13Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16 | Phase 3 | Active, not recruiting | Drug: Deucravacitinib, Apremilast · Other: Placebo | Psoriatic Arthritis | 729 | 2021-07-15 | 2024-02-06actual | — | 2025-06-13 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic ArthritisNCT05195814results2025-03-30observationalChange From Baseline to 6 Months in Tender Joint Count (68) | — | Completed | — | Psoriatic Arthritis | 141 | 2021-11-15 | 2023-10-31actual | — | 2025-03-30 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic ArthritisNCT03783026results2022-12-19Change From Baseline in the Composite Score of BME, Synovitis, and Tenosynovitis Assessed by PsAMRIS at Week 24 | Phase 4 | Completed | Drug: Apremilast | Psoriatic Arthritis | 123 | 2019-02-06 | 2021-10-26actual | — | 2025-02-21 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisNCT05511519Proportion of patients achieving ACR20 at Week 12 | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: ATI-450, Placebo Oral Tablet | Psoriatic Arthritis | 47 | 2022-07-12 | 2023-12-06actual | — | 2024-11-27 |
| AMGN | Amgen | $229.9B | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.NCT03747939results2024-01-05Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 | Phase 4 | Completed | Drug: Apremilast (CC-10004) · Other: Apremilast (CC-10004) Placebo | Arthritis, Psoriatic | 310 | 2018-12-31 | 2022-12-19actual | — | 2024-10-22 |
| NVS | Novartis | — | Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims DatabaseNCT06600009observationalNumber of Patients with Persistence of Secukinumab Treatment at One Year | — | Completed | Drug: Secukinumab, Adalimumab | Psoriatic Arthritis | 534 | 2022-10-17 | 2023-08-21actual | — | 2024-09-19 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) | Phase 2 | Completed | Drug: Sonelokimab, Placebo, Adalimumab | Arthritis, Psoriatic | 207 | 2022-12-13 | 2023-09-05actual | — | 2024-09-05 |
| PFE | Pfizer | $155.3B | Korean Post-marketing Surveillance for XeljanzNCT02984020results2024-08-27observationalNumber of Participants With Adverse Events (AEs), Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) | — | Completed | — | Rheumatoid Arthritis, Psoriatic Arthritis | 1,041 | 2016-05-13 | 2022-06-09actual | — | 2024-08-27 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic ArthritisNCT04758117observationalPercentage of Participants Receiving Upadacitinib who Attain Minimal Disease Activity (MDA) | — | Completed | — | Psoriatic Arthritis | 394 | 2021-02-04 | 2023-07-26actual | — | 2024-07-17 |
| AMGN | Amgen | $229.9B | Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)NCT03608657observationalThe rate of achieving Low Disease Activity (LDA) | — | Completed | Drug: Apremilast | Arthritis, Psoriatic | 102 | 2018-07-31 | 2021-04-12actual | — | 2024-06-05 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological TreatmentNCT03828045observationalTreatment persistence at 6 months after initiating apremilast treatment | — | Completed | Drug: Apremilast | Arthritis, Psoriatic | 119 | 2019-02-06 | 2021-10-20actual | — | 2024-06-05 |
| PFE | Pfizer | $155.3B | Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic ArthritisNCT03486457results2024-02-08Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 3 | Phase 3 | Completed | Drug: Tofacitinib, Tofacitinib · Other: Placebo | Psoriatic Arthritis | 204 | 2018-08-10 | 2021-04-28actual | — | 2024-02-08 |
| AMGN | Amgen | $229.9B | A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The NetherlandsNCT02875184observationalPercentage of patients with a Health Assessment Questionnaire - Disability Index (HAQ-DI) score of ≤ 0.5 or with a decrease of ≥ 0.3 of the HAQ-DI score compared with baseline | — | Completed | — | Arthritis, Psoriatic | 200 | 2017-03-06 | 2022-06-30actual | — | 2023-10-10 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Phase 3 Clinical Study of KHK 4827NCT02052609Incidence and types of adverse events and adverse reactions | Phase 3 | Completed | Drug: KHK4827 140mg SC, KHK4827 210mg SC | Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma | 155 | Feb 2014 | 2015-01-28actual | — | 2023-08-25 |
| PFE | Pfizer | $155.3B | National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real LifeNCT02925338results2023-01-25observationalPercentage of Participants Without Treatment Failure During 2-Years of Observation | — | Completed | Other: QOL questionaire | Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 1,431 | 2016-10-19 | 2021-04-12actual | — | 2023-01-25 |
| BIIB | Biogen | $31.4B | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyNCT03662919observationalPercentage of Participants who are Still Treated with Either Flixabi or Imraldi at 12 Months | — | Completed | Drug: Infliximab, Adalimumab | Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Crohn's Disease, Colitis, Ulcerative | 2,274 | 2018-07-02 | 2022-06-30actual | — | 2022-10-18 |
| AMGN | Amgen | $229.9B | Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic ArthritisNCT02376790results2019-02-22Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 | Phase 3 | Completed | Drug: Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate | Psoriatic Arthritis | 851 | 2015-03-03 | 2018-01-09actual | — | 2022-09-21 |
| AMGN | Amgen | $229.9B | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)NCT01307423results2014-08-15Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 | Phase 3 | Completed | Drug: Apremilast 20mg, Apremilast 30mg, Placebo | Psoriatic Arthritis | 529 | 2010-12-09 | 2013-02-21actual | — | 2022-06-14 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety and Effectiveness of Abatacept in Psoriatic Arthritis ParticipantsNCT03419143observationalDisease Activity index for PSoriatic Arthritis (DAPSA) | — | Completed | — | Psoriatic Arthritis (PsA) | 190 | 2018-03-02 | 2022-03-31actual | — | 2022-05-31 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyNCT04115748results2022-05-16Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12 | Phase 3 | Terminatedsponsor's stated reason: Development program terminated | Drug: Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab | Psoriatic Arthritis | 67 | 2019-12-03 | 2021-01-19actual | — | 2022-05-16 |
| BMY | Bristol-Myers Squibb | $134.9B | Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic ArthritisNCT01860976results2017-08-02Proportion of ACR 20 Responders at Day 169 | Phase 3 | Completed | Drug: Abatacept, Placebo | Psoriatic Arthritis | 489 | 2013-06-17 | 2015-07-14actual | — | 2022-04-05 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD TherapyNCT04115839results2022-03-18Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12 | Phase 3 | Terminatedsponsor's stated reason: Development program terminated | Drug: Filgotinib, Placebo to match filgotinib | Psoriatic Arthritis | 106 | 2019-11-13 | 2021-01-04actual | — | 2022-03-18 |
| AMGN | Amgen | $229.9B | Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque PsoriasisNCT01690299results2015-08-04Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline | Phase 3 | Completed | Drug: Apremilast, Etanercept, Placebo tablet, Placebo injection | Psoriasis, Psoriatic Arthritis | 250 | 2012-10-01 | 2014-07-03actual | — | 2022-03-15 |
| BMY | Bristol-Myers Squibb | $134.9B | Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)NCT03881059results2021-05-17Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16 | Phase 2 | Completed | Other: BMS-986165 Placebo, Ustekinumab Placebo · Drug: BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab | Active Psoriatic Arthritis | 203 | 2019-04-01 | 2020-04-27actual | — | 2022-02-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic ArthritisNCT00245960results2009-05-27Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis | Phase 4 | Completed | Drug: etanercept, etanercept, Placebo | Psoriatic Arthritis | 752 | 2005-12-27 | 2008-03-29actual | — | 2022-01-31 |
| PFE | Pfizer | $155.3B | Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)NCT04428502results2021-09-14observationalChange From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 1 | — | Completed | Drug: Enbrel | Psoriatic Arthritis | 127 | 2020-07-05 | 2020-08-30actual | — | 2021-09-14 |
| PFE | Pfizer | $155.3B | A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic ArthritisNCT03963401results2021-08-04Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16 | Phase 2 | Completed | Drug: PF-06700841 · Other: Placebo | Psoriatic Arthritis | 219 | 2019-06-13 | 2020-04-06actual | — | 2021-08-04 |
| ABBV | AbbVie | $457.5B | A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)NCT02814175results2020-11-23Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1) | Phase 4 | Completed | Drug: methotrexate (MTX) · Biological: adalimumab (ADA) | Psoriatic Arthritis | 246 | 2016-08-05 | 2019-09-23actual | — | 2020-11-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic ArthritisNCT03151551results2019-04-02Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100) | Phase 4 | Completed | Drug: Ixekizumab, Adalimumab | Psoriatic Arthritis | 566 | 2017-08-24 | 2018-11-15actual | — | 2020-11-03 |
| ABBV | AbbVie | $457.5B | A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian FederationNCT02988674observationalProportion of participants on adalimumab therapy | — | Completed | — | Spondylarthritis, Psoriatic Arthritis, Ankylosing Spondylitis (AS) | 139 | 2016-12-22 | 2019-10-16actual | — | 2020-10-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic ArthritisNCT02349295results2017-12-14Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) | Phase 3 | Completed | Drug: Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W | Psoriatic Arthritis | 363 | 2014-12-31 | 2016-09-09actual | — | 2020-07-01 |
| AMGN | Amgen | $229.9B | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic ArthritisNCT00456092results2019-10-23Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12 | Phase 2 | Completed | Drug: Apremilast, Placebo | Psoriatic Arthritis | 204 | 2007-03-05 | 2009-05-09actual | — | 2020-06-19 |
| AMGN | Amgen | $229.9B | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisNCT01172938results2014-05-20Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 | Phase 3 | Completed | Drug: Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast | Psoriatic Arthritis | 504 | 2010-06-02 | 2012-04-27actual | — | 2020-06-19 |
| PFE | Pfizer | $155.3B | Open-Label Extension Study Of Tofacitinib In Psoriatic ArthritisNCT01976364results2020-05-21Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 3 | Completed | Drug: Tofacitinib, Tofacitinib, Methotrexate, Placebo Methotrexate | Arthritis, Psoriatic | 686 | 2014-02-17 | 2019-05-20actual | — | 2020-05-21 |
| AMGN | Amgen | $229.9B | Safety and Efficacy Study of Apremilast to Treat Psoriatic ArthritisNCT01925768results2016-06-13Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16 | Phase 3 | Completed | Drug: Apremilast 30 mg, Placebo | Psoriatic Arthritis | 219 | 2013-09-04 | 2015-02-25actual | — | 2020-05-12 |
| AMGN | Amgen | $229.9B | Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type PsoriasisNCT01988103results2020-03-20Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16 | Phase 2 | Completed | Drug: Apremilast, Apremilast, Placebo | Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica | 254 | 2013-07-09 | 2014-11-20actual | — | 2020-05-07 |
| AMGN | Amgen | $229.9B | PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisNCT01212757results2014-05-19Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 | Phase 3 | Completed | Drug: Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast | Psoriatic Arthritis | 488 | 2010-09-27 | 2012-07-26actual | — | 2020-05-06 |
| AMGN | Amgen | $229.9B | PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisNCT01212770results2014-05-20Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 | Phase 3 | Completed | Drug: Apremilast 20mg, Apremilast 30mg, Placebo | Psoriatic Arthritis | 505 | 2010-09-30 | 2012-08-21actual | — | 2020-05-06 |
| AMGN | Amgen | $229.9B | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in BelgiumNCT03096990observationalProportion of patients showing response assessed by improvement for at least 2 out of 4 measures which compose the Psoriatic Arthritis Response Criteria (PsARC) at 6 months after apremilast initiation with respect to baseline | — | Completed | Drug: apremilast | Arthritis, Psoriatic | 106 | 2017-04-21 | 2018-12-27actual | — | 2020-04-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Investigate BMS-986165 and Methotrexate in Healthy Male PatientsNCT03402087Maximum observed plasma concentration (Cmax) | Phase 1 | Completed | Drug: Methotrexate, Leucovorin, BMS-986165 | Lupus, Psoriatic Arthritis | 30 | 2018-01-08 | 2018-03-20actual | — | 2020-02-25 |
| ABBV | AbbVie | $457.5B | Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceNCT03223012observationalProportion of patients with Medication Possession Ratio (MPR)>=80% | — | Completed | — | Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis (AS), Non-radiographic Axial Spondyloarthritis | 116 | 2017-11-15 | 2019-02-28actual | — | 2020-02-24 |
| PFE | Pfizer | $155.3B | Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From RemicadeNCT02605642results2020-01-13observationalTreatment Persistence With CT-P13 in Participants With Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) | — | Completed | Drug: CT-P13 | Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 351 | 2015-09-10 | 2018-12-31actual | — | 2020-01-13 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Phase 4 Clinical Study of BrodalumabNCT04183881Incidence and types of adverse events and adverse reactions | Phase 4 | Completed | Drug: Brodalumab 210mg SC | Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma | 138 | 2016-07-04 | 2017-01-10actual | — | 2019-12-09 |
| LLY | Eli Lilly and Company | $1.15T | A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic ArthritisNCT02584855results2019-11-15Double-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA]) | Phase 3 | Completed | Drug: Ixekizumab, Placebo | Psoriatic Arthritis | 394 | 2015-09-14 | 2018-10-30actual | — | 2019-11-15 |
| ABBV | AbbVie | $457.5B | Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)NCT02750800results2019-11-06observationalMean Change From Baseline in Short Form 36 Version 2.0 (SF-36 V2) Physical Component Summary (PCS) Score at 12 Months | — | Completed | Biological: Adalimumab · Behavioral: AbbVie Care 2.0 | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis | 427 | 2016-04-07 | 2018-04-03actual | — | 2019-11-06 |
| PFE | Pfizer | $155.3B | A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.NCT02486302results2019-06-24observationalNumber of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 | — | Completed | Drug: Etanercept | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis | 1,534 | 2015-03-24 | 2017-12-11actual | — | 2019-06-24 |
| ABBV | AbbVie | $457.5B | BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisNCT02719171results2019-05-30Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16 | Phase 2 | Completed | Drug: risankizumab, placebo for risankizumab | Arthritis, Psoriatic | 185 | Apr 2016 | May 2017actual | — | 2019-05-30 |
| ABBV | AbbVie | $457.5B | A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)NCT02986373results2019-05-28Number of Participants With Adverse Events | Phase 2 | Completed | Biological: risankizumab | Psoriatic Arthritis | 145 | 2016-12-15 | 2018-07-08actual | — | 2019-05-28 |
| ABBV | AbbVie | $457.5B | Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeNCT01768858results2019-01-28observationalChange From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months | — | Completed | Drug: Adalimumab | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease, Ulcerative Colitis, Plaque Psoriasis | 96 | 2013-02-05 | 2017-08-13actual | — | 2019-01-28 |
| ABBV | AbbVie | $457.5B | Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in BelgiumNCT01845818results2019-01-09observationalChange From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Combined) | — | Completed | — | Ankylosing Spondylitis, Psoriatic Arthritis | 183 | 2013-06-05 | 2017-06-23actual | — | 2019-01-09 |
| ABBV | AbbVie | $457.5B | Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])NCT02414633results2018-10-16observationalWork Productivity and Activity Impairment Psoriatic Arthritis Questionnaire (WPAI:PsA) Percentage of Overall Work Impairment (OWI): Change From Baseline to Week 24 | — | Completed | — | Psoriatic Arthritis | 148 | 2015-04-01 | 2017-03-13actual | — | 2018-10-16 |
| AMGN | Amgen | $229.9B | Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject EtanerceptNCT01901185results2014-11-21Percentage of Successful Self-injections to Total Non-missed Injections | Phase 3 | Completed | Drug: Etanercept / Autoinjector A | Rheumatoid Arthritis, Psoriatic Arthritis | 77 | 2013-06-11 | 2013-12-18actual | — | 2018-09-04 |
| PFE | Pfizer | $155.3B | Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF InhibitorsNCT01882439results2017-09-15Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 | Phase 3 | Completed | Drug: Tofacitinib, Tofacitinib, Tofacitinib, Tofacitinib · Other: Placebo, Placebo | Psoriatic Arthritis | 395 | Aug 2013 | Apr 2016actual | — | 2017-09-15 |
| ABBV | AbbVie | $457.5B | A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)NCT02349451results2017-08-04American College of Rheumatology (ACR) 20 Response Rate at Week 12: ABT-122 Versus Placebo | Phase 2 | Completed | Biological: adalimumab, ABT-122 | Psoriatic Arthritis | 240 | 2015-04-28 | 2016-07-04actual | — | 2017-08-04 |
| PFE | Pfizer | $155.3B | Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator StudyNCT01877668results2017-07-06Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3 | Phase 3 | Completed | Drug: Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo, Placebo | Psoriatic Arthritis | 422 | 2014-01-20 | 2015-12-18actual | — | 2017-07-06 |
| ABBV | AbbVie | $457.5B | To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)NCT02028169results2017-04-27observationalWork Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) Up to Month 9 | — | Completed | — | Psoriatic Arthritis, Work Productivity | 120 | Jan 2014 | Apr 2016actual | — | 2017-04-27 |
| ABBV | AbbVie | $457.5B | A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197NCT02429895American College of Rheumatology (ACR) 20 response rate by visit | Phase 2 | Terminatedsponsor's stated reason: Internal business decision | Drug: ABT-122 | Psoriatic Arthritis | 168 | Oct 2015 | May 2016actual | — | 2016-06-17 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic ArthritisNCT00659412Proportion of patients achieving a score in the assessment system of the American College of Rheumatology Core Set Measurements of ACR 20, ACR 50 and ACR 70 | Phase 2 | Completed | Drug: Alefacept, Methotrexate, Placebo | Psoriatic Arthritis | 185 | Sep 2003 | Mar 2005actual | — | 2014-09-18 |
| AMGN | Amgen | $229.9B | REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)NCT00127842results2014-04-24Percentage of Participants With Improvement of ≥ 0.50 Units From Baseline to Month 24 in the HAQ DI | Phase 4 | Completed | Drug: Etanercept | Psoriatic Arthritis | 110 | Aug 2005 | Aug 2005actual | — | 2014-04-24 |
| PFE | Pfizer | $155.3B | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by DermatologistsNCT00293709results2014-02-26observationalPercentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) | — | Completed | Drug: etanercept | Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous | 129 | Jan 2006 | Feb 2013actual | — | 2014-02-26 |
| PFE | Pfizer | $155.3B | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by RheumatologistsNCT00293722results2014-02-26observationalPercentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) | — | Completed | Drug: Etanercept | Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous | 1,308 | Jan 2006 | Feb 2013actual | — | 2014-02-26 |
| PFE | Pfizer | $155.3B | Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic ArthritisNCT00938015results2013-05-27observationalPercentage of Participants With at Least 1 Serious Adverse Event (SAE): Baseline up to Year 1 | — | Completed | Other: Questionnaire, Questionnaire | Arthritis, Psoriatic | 303 | Oct 2004 | Apr 2012actual | — | 2013-05-27 |
| PFE | Pfizer | $155.3B | Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque PsoriasisNCT00998829observationalTo evaluate the prevalence of undiagnosed psoriatic arthritis in patients presenting with plaque psoriasis using the PASE (Psoriatic Arthritis Screening and Evaluation) questionnaire based on a score of ≥ 44 on the questionnaire | — | Completed | Other: questionnaire | Arthritis, Psoriatic, Psoriasis | 458 | May 2010 | May 2012actual | — | 2012-11-29 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic ArthritisNCT00534313results2010-11-22Long-term Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, and AEs of Interest | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy with respect to skin-related lesions in the short-term phase | Drug: Abatacept, Placebo | Psoriatic Arthritis | 191 | Nov 2007 | Dec 2008actual | — | 2012-08-01 |
| PFE | Pfizer | $155.3B | Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology PracticeNCT01147874results2012-06-21Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results | Phase 4 | Completed | Procedure: lab draws and imaging | Psoriasis, Psoriatic Arthritis | 1,013 | Aug 2010 | Jul 2011actual | — | 2012-06-21 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic ArthritisNCT00273858results2011-07-28observationalNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | — | Terminatedsponsor's stated reason: The study was terminated because at least one year follow-up was achieved for each patient and the achievement of 965 exposure years to the drug. | Other: There is no Intervention. The study is observational. | Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Spondylitis, Ankylosing | 880 | Mar 2006 | Jul 2010actual | — | 2011-09-12 |
| AMGN | Amgen | $229.9B | Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and PsoriasisNCT00317499 | Phase 3 | Completed | Other: Placebo · Drug: Etanercept | Psoriatic Arthritis, Psoriasis | 205 | Apr 2000 | Jun 2002actual | — | 2010-12-23 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in AustraliaNCT00751387observationalProportion of rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis patients in defined disease severity categories | — | Completed | — | Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis | 559 | Nov 2008 | Sep 2009actual | — | 2010-11-30 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating the Safety of Enbrel (Etanercept)NCT00683384results2010-11-16observationalNumber of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection | — | Completed | Drug: Etanercept (Enbrel) | Arthritis, Psoriatic | 93 | Jan 2007 | Oct 2009actual | — | 2010-11-16 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic ArthritisNCT00580632observationalDetermine diagnosis and evolution time of patients | — | Completed | — | Psoriatic Arthritis | 300 | Jan 2007 | Sep 2007actual | — | 2010-05-14 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Etanercept and Methotrexate in Plaque PsoriasisNCT00161655Proportion of pts whose plaque psoriasis is cleared or almost cleared after 24 weeks. | Phase 4 | Completed | Drug: Etanercept, Methotrexate | Psoriasis, Arthritis, Psoriatic | 60 | Apr 2005 | Aug 2006actual | — | 2009-09-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Psoriatic Arthritis is matched — 5 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Psoriatic Arthritis
- Arthritis, Psoriatic
- Juvenile Psoriatic Arthritis
- Psoriatic Arthritis (PsA)
- Active Psoriatic Arthritis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Psoriatic Arthritis” (a text search, wider than this page)